Capricor Therapeutics, Inc. (CAPR) Stock Score, Valuation & Financial Research

Capricor Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for CAPR

Capricor Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 7.75. These figures are a research snapshot, not a buy or sell recommendation.

What Capricor Therapeutics, Inc. does

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Capricor Therapeutics is a clinical-stage biotechnology company that generates revenue primarily through strategic collaborations and licensing agreements. The company focuses on the development of cell and exosome-based therapeutics, monetizing its intellectual property and technology platforms through milestone payments and research and development funding from partners.

Products and services

  • The company develops cell and exosome-based therapeutics, including its lead candidate deramiocel for Duchenne muscular dystrophy and the StealthX exosome platform for vaccine and therapeutic applications.

Brands and product families

  • StealthX — Exosome platform for vaccine and therapeutic applications. Source

Customer types

Pharmaceutical and biotechnology companies via strategic collaborations.

Disclosed major customers

  • Nippon Shinyaku Co., Ltd. Source

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of clinical trial materials and potential commercial supply; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Nippon Shinyaku Co., Ltd. — Exclusive distribution and commercialization agreement for deramiocel in the United States and Japan. Source

Competitors and product-market comparisons

  • Sarepta Therapeutics, Inc. — Competes in the development of therapies for Duchenne muscular dystrophy. Source
  • Pfizer Inc. — Competes in the development of therapies for Duchenne muscular dystrophy. Source

Business strengths to evaluate

  • Proprietary cell and exosome-based technology platforms Source
  • Strategic partnership with Nippon Shinyaku Source

Business risks and research considerations

  • Significant dependence on a single collaboration partner Source
  • Risks associated with clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

CAPR financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 7.75
Market capitalization:
445.71M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -129.42M
Free cash flow:
USD -72.72M
Cash:
USD 20.94M
Total debt:
USD 91.05M
EPS:
USD -2.45

What stands out

  • Free cash flow is USD -72.72M, negative for the stored period.
  • The balance sheet shows USD 20.94M of cash versus USD 91.05M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Debt exceeds cash by USD 70.11M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for CAPR

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can CAPR fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Is CAPR's debt load manageable relative to cash generation, interest costs and upcoming maturities?
  • What specifically needs to improve for CAPR to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of CAPR's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research CAPR

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.